A potential therapeutic effect of catalpol in Duchenne muscular dystrophy revealed by binding with TAK1.

Dengqiu XuLei ZhaoJingwei JiangSijia LiZeren SunXiaofei HuangChunjie LiTao WangLixin SunXihua LiZhen-Zhou JiangLuyong Zhang

Published in: Journal of cachexia, sarcopenia and muscle (2020)

Our findings show that catalpol and TAK1 inhibitors substantially improve whole-body muscle health and the function of dystrophic skeletal muscles and may provide a novel therapy for DMD.

Keyphrases

duchenne muscular dystrophy
public health
healthcare
skeletal muscle
mental health
muscular dystrophy
health information
dna binding
binding protein
human health
social media